We Know Where New Weight Loss Drugs Came From, but Not Why T

Every so often a drug comes along that has the potential to change the world. Medical specialists say the latest to offer that possibility are the new drugs that treat obesity — Ozempic, Wegovy, Mounjaro and more that may soon be coming onto the market. It’s early, but nothing like these drugs has existed before. “Game changers,” said Jonathan Engel, a historian of medicine and health care policy at Baruch College in New York. Sign up for The Morning newsletter from the New York Times Obesity af

Related Keywords

Michigan , United States , New York , Mount School , Toronto , Ontario , Canada , Copenhagen , Køavn , Denmark , Germany , Munich , Bayern , Norway , American , John Eng , Eli Lilly , David Dalessio , Jens Juul Holst , Caroline Apovian , Joel Habener , Daniel Drucker , Randy Seeley , Martin Holst Lange , Krogsgaard Thomsen , Susan Yanovski , Ambre James Brown , Lotte Bjerre Knudsen , Jonathan Engel , Rudolph Leibel , Jeffrey Mechanick , Matthias Tsch , Indiana University , Amylin Pharmaceuticals , Mount Sinai Icahn School Of Medicine , University Of Copenhagen , Amgen , Endocrine Society , Lunenfeld Tanenbaum Research Institute , Columbia University Irving Medical Center , Jeffrey Friedman At Rockefeller University , Novo Nordisk Foundation , New York Times , Harvard Medical School , Drug Administration , Baruch College , National Institutes Of Health , York Times Company , National Institute Of Diabetes , Veterans Affairs Medical Center , Novo Nordisk , University Of Michigan , Davidd Alessio , National Institute , Kidney Diseases , New York City , National Institutes , Jeffrey Friedman , Rockefeller University , Helmholtz Munich , Richard Di Marchi , Mads Krogsgaard Thomsen , Mount Sinai , Icahn School , Weight Management , Columbia University Irving Medical , Weight Loss ,